Articles Accuse Makary of Putting Reputation Over Science - Tobacco Reporter
Articles accuse FDA Commissioner Marty Makary of prioritizing reputation over scientific evidence in regulating reduced-harm nicotine products.Summary
Recent reports from The Wall Street Journal and the Brownstone Institute criticize FDA Commissioner Marty Makary for allegedly allowing reputational concerns to influence decisions regarding reduced-harm nicotine products. The Wall Street Journal reported tensions between the White House, which favors expanding access to flavored vaping products, and Makary, who has reportedly blocked authorizations despite internal scientific support. A specific case involving vape company Glas illustrates this divergence, where FDA scientists recommended flavor approvals, but a memo from Makary’s office delayed the decision. Roger Bate of the Brownstone Institute further argues that regulatory progress has stalled despite declining youth vaping rates and supporting harm reduction evidence, attributing this slowdown to Makary’s reluctance to act based on scientific data rather than reputational risk.
(Source：Tobacco Reporter)
